Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy Volunteers
NCT ID: NCT05407779
Last Updated: 2024-01-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
39 participants
INTERVENTIONAL
2021-01-22
2023-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects
NCT05974969
Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers
NCT02393950
Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers
NCT02731469
Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers
NCT01605461
A Study to Test the Safety, and Tolerability of Padsevonil in Healthy Male Japanese Study Participants
NCT04075409
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
Subjects will be monitored for 14 days following drug administration to assess the presence of dose limiting toxicity (DLT). In the absence of DLT, another cohort with a higher dose level will be formed.
After all subjects have completed the main study period (Days 1-57), the safe dose range of BCD-180 will be determined based on assessed PD, PK, safety and immunogenicity endpoints.
Further follow-up of the subjects included in stage 1 will continue up to a year.
Stage 2. Two cohorts of healthy Asian volunteers (Cohorts 8 and 9) will be included. Subjects will receive a single infusion of BCD-180 at selected doses planned for further clinical development based on the results of the main period of stage 1.
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
The Cohort 1 include one subject ("sentinel volunteer") to receive BCD-180 at a dose 1
BCD-180, dose 1
anti-TRBV9 monoclonal antibody single infusion at dose 1
Cohort 2
The Cohort 2 include 3 subjects to receive BCD-180 at a dose 2
BCD-180, dose 2
anti-TRBV9 monoclonal antibody, single infusion at dose 2
Cohort 3
The Cohort 3 include 3 subjects to receive BCD-180 at a dose 3
BCD-180, dose 3
anti-TRBV9 monoclonal antibody, single infusion at dose 3
Cohort 4
The Cohort 4 include 3 subjects to receive BCD-180 at a dose 4
BCD-180, dose 4
anti-TRBV9 monoclonal antibody, single infusion at dose 4
Cohort 5
The Cohort 5 include 3 subjects to receive BCD-180 at a dose 5
BCD-180, dose 5
anti-TRBV9 monoclonal antibody, single infusion at dose 5
Cohort 6
The Cohort 6 include 3 subjects to receive BCD-180 at a dose 6
BCD-180, dose 6
anti-TRBV9 monoclonal antibody, single infusion at dose 6
Cohort 7
The Cohort 7 include 3 subjects to receive BCD-180 at a dose 7
BCD-180, dose 7
anti-TRBV9 monoclonal antibody, single infusion at dose 7
Cohort 8
The Cohort 8 include 3 subjects to receive BCD-180 at one of two selected for the further development doses
BCD-180, dose 6
anti-TRBV9 monoclonal antibody, single infusion at dose 6
Cohort 9
The Cohort 9 include 3 subjects to receive BCD-180 at one of two selected for the further development doses
BCD-180, dose 7
anti-TRBV9 monoclonal antibody, single infusion at dose 7
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BCD-180, dose 1
anti-TRBV9 monoclonal antibody single infusion at dose 1
BCD-180, dose 2
anti-TRBV9 monoclonal antibody, single infusion at dose 2
BCD-180, dose 3
anti-TRBV9 monoclonal antibody, single infusion at dose 3
BCD-180, dose 4
anti-TRBV9 monoclonal antibody, single infusion at dose 4
BCD-180, dose 5
anti-TRBV9 monoclonal antibody, single infusion at dose 5
BCD-180, dose 6
anti-TRBV9 monoclonal antibody, single infusion at dose 6
BCD-180, dose 7
anti-TRBV9 monoclonal antibody, single infusion at dose 7
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Men aged 18 to 45 inclusive at the time of ICF signing.
3. For stage 2: Asian race.
4. The ability of the subject to follow the Protocol procedures, according to the investigator.
5. A diagnosis of "health" established using standard clinical, laboratory tests and investigations carried out at screening, according to the investigator, as well as medical history data (no acute or chronic respiratory, gastrointestinal, cardiovascular, nervous system diseases, hepatic or renal impairment).
6. Hemodynamic parameters within normal limits: systolic blood pressure (SBP) within 100-130 mm Hg, diastolic blood pressure (DBP) within 60-90 mm Hg, pulse rate within 60-90 bpm.
7. Willingness of subjects and their female sexual partners of childbearing potential to use reliable contraception from the ICF signing throughout the main period of the study and during Day 57 of the main period of the study. This requirement does not apply to subjects who have had surgical sterilization. Reliable methods of contraception involve the use of one barrier method in combination with one of the following in the female partner: spermicides, intrauterine device/oral contraceptives.
8. Willingness to refrain from participating in any other clinical trials, starting from the ICF signing, throughout the main study period and during Day 57 of the main study period, and in other clinical trials involving the administration of any drugs that affect the human immune system, including other monoclonal antibody products with immunosuppressive action, during the current study, i.e., until the end of participation in it.
Exclusion Criteria
2. Any confirmed or suspected immunosuppressive or immunodeficient condition.
3. Any acute infectious or non-infectious disease, including convalescence, less than 4 weeks from clinical recovery, as well as during the screening.
4. A diagnosis of infectious mononucleosis (either documented or reported by the subject) made within 2 months prior to the ICF signing or during the screening.
5. BCG (Bacillus Calmette-Guérin vaccine) vaccination (within 12 weeks), administration of live vaccines (within 8 weeks) or any other vaccines (within 4 weeks) before signing the ICF or during the screening.
6. Medical history of allergic reactions and evidence of other significant adverse reactions after administration of any medicinal products.
7. Hypersensitivity to any of the BCD-180 ingredients or premedication drugs.
8. Body mass index (BMI) outside of the normal range (18.0-30.0 kg/m2).
9. Results of standard laboratory and imaging tests that fall beyond the reference intervals adopted at the study center.
10. Positive screening tests for HIV infection, hepatitis B and C, syphilis, tuberculosis.
11. Positive urine test for psychotropic, narcotic, psychoactive drugs or saliva alcohol test at screening.
12. Impossibility of venipuncture to collect blood samples (for example, due to skin disease at venipuncture sites).
13. Long-term (more than 14 days) use of drugs that have a pronounced effect on hemodynamics, liver function, etc. (barbiturates, omeprazole, cimetidine, etc.) less than 30 days before the ICF signing; prior use of drugs that affect the immune system, including other monoclonal antibody products, with immunosuppressive action.
14. Regular oral or parenteral administration of any medicinal products, including over-the-counter drugs, vitamins and dietary supplements, less than 14 days before the ICF signing.
15. Smoking more than 10 cigarettes a day.
16. Consumption of more than 10 units of alcohol per week (1 unit of alcohol is equivalent to ½ L of beer, 200 mL of wine or 20 mL of spirits) or a history of alcoholism, drug addiction or drug abuse.
17. Surgical interventions performed less than 90 days before the ICF signing.
18. Donation of 450 mL or more of blood or plasma within 60 days prior to the ICF signing.
19. Participation in any clinical studies of medicinal products less than 90 days prior to the ICF signing; previous participation in this study in case of administration of the investigational product .
20. For stage 2: a history of coronavirus infection (positive polymerase chain reaction (PCR) test for SARC-CoV2-RNA) within 8 weeks prior to the ICF signing.
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biocad
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
X7 Clinical Research
Saint Petersburg, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BCD-180-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.